Antineoplastic effect of anastrozole-loaded polymer nanocapsules on malignant human breast cancer cells (MCF-7)

The fundamental reason in chemotherapy’s failure to treat breast cancer (BC) is therapy confrontation. BC is frequently treated with anastrozole (ANZ), a non-steroidal aromatase inhibitor. But, its incomplete bioavailability and side effects necessitate improved drug delivery system. This study intended to increase the cytotoxicity impact of ANZ by loading it in polymeric nanocapsules (ANZ-PNCs) in MCF-7 via increasing IC50 and apoptosis. Polymeric nanocapsules (PNCs) prepared using an emulsion-based method, And particle dimension and morphology were characterized via field emission scanning electron microscopy (FESEM) and dynamic light scattering (DLS). UV-vis spectroscopy was used to measure the encapsulation efficiency (E.E.%) of ANZ-loaded PNCs. Apoptosis induction was assessed by Flow Cytometry, Anexxin V-FITC/PI labeling, BAX, P53, BCL-2 genes using real-time PCR, and caspase-3,-8, and − 9 activity assays. The synthesized ANZ-PNCs showed a uniform spherical shape with an average size 10 nm. Drug loading content (LC%) was 3.2 ± 0.4 and the EE% was 74.6 ± 2.3. In vitro cytotoxicity assay by MTT test revealed ANZ-loaded PNCs (9 µg/mL) achieved similar therapeutic effects than free ANZ (48 µg/mL). BAX and P53 expression significantly increased (3.3 (P < 0.01) and 2.8 (P < 0.05) times, respectively); contrarywise, BCL-2 was decreased versus untreated controls. Caspase-3, and − 9 levels (P < 0.001) and caspase − 8 (P < 0.01) were elevated after ANZ-loaded PNCs administration. Morphological studies revealed nuclear fragmentation and cell shape changes after giving 9 µg/mL ANZ-PNCs, indication apoptosis induction. Strong matches, the ANZ loaded PNCs can be used to deliver ANZ for breast cancer chemotherapy of breast cancer.